CompletedNot Applicable

Effectiveness of 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding

South Korea348 participantsStarted 2018-11-01

Plain-language summary

A prospective, multi-center, randomized controlled trial to evaluate safety and effectiveness of endoscopic hemostatic powder, 'Nexpowder' for hemostatic treatments of nonvariceal upper gastrointestinal bleeding. This study is a prospective, multi-center, single blind (for patients), controlled investigation planned to evaluate safety and effectiveness of Nexpowder with 352 subject patients.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult male or female with age of older than 19 years. * Patients showing non-variceal upper GI bleeding symptoms * An endoscopic examination indicates that the patients's ulcer is categorized Class Ia, Ib, or IIa according to the Forrest Classifications. Exclusion Criteria: * Pregnant or breast-feeding patients

What they're measuring

The rates of re-bleeding

Timeframe: 3 days

Trial details

NCT IDNCT04124588

SponsorNext Biomedical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-10-12

View on ClinicalTrials.gov More Nonvariceal Upper Gastrointestinal Bleeding trials